The compound you described, **(r,s)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one**, is a chiral molecule with the following key features:
* **Benzofuran-2-one core:** This is the central structural component of the molecule. Benzofuran-2-one is a heterocyclic compound with a fused benzene ring and a five-membered furan ring, and the 2-one indicates a ketone functionality on the furan ring.
* **5,7-di-tert-butyl substituents:** The two tert-butyl groups are bulky, nonpolar groups attached to the benzene ring at positions 5 and 7. These groups can influence the molecule's conformation and interactions with other molecules.
* **3-hydroxy-3-trifluoromethyl:** This portion of the molecule contains a hydroxyl group (OH) and a trifluoromethyl group (CF3) attached to the same carbon (position 3) on the furan ring. The trifluoromethyl group is a very electron-withdrawing group, which can significantly affect the molecule's properties.
* **(r,s) designation:** This indicates that the molecule is a racemate, meaning it contains an equal mixture of both enantiomers (non-superimposable mirror images) of the compound.
**Importance in Research:**
While there is limited information publicly available on this specific compound, its structural features and functionality suggest potential applications in various research areas:
* **Pharmaceutical Chemistry:** The benzofuran-2-one core is known for its potential bioactivity. The presence of the trifluoromethyl group and hydroxyl group could enhance its interactions with biological targets and potentially lead to interesting pharmacological effects.
* **Organic Synthesis:** The bulky tert-butyl groups and the trifluoromethyl group could make this molecule a valuable building block in organic synthesis, allowing the construction of complex molecules with unique properties.
* **Materials Science:** The molecule's structure and properties could make it suitable for applications in materials science, for example, as a component in polymers or coatings with specific properties.
**Further research:**
To understand the specific importance of this compound, further research is necessary. This could involve:
* **Synthesis and characterization:** Developing efficient synthetic routes to produce the compound and thoroughly characterizing its physical and chemical properties.
* **Biological activity studies:** Testing the compound's potential bioactivity against various biological targets, such as enzymes, receptors, or cancer cells.
* **Computational studies:** Using computational methods to predict and understand the compound's behavior, including its structure-activity relationships, interactions with other molecules, and potential applications.
**Remember:** It's crucial to consult reliable scientific databases and publications for the most accurate and up-to-date information regarding the specific compound (r,s)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one.
(R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one: a positive allosteric modulator of GABAB receptors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 4332683 |
CHEMBL ID | 2322946 |
SCHEMBL ID | 2371840 |
MeSH ID | M0525702 |
Synonym |
---|
EU-0053641 |
5,7-ditert-butyl-3-hydroxy-3-(trifluoromethyl)-1-benzofuran-2-one |
(3s)-5,7-ditert-butyl-3-hydroxy-3-(trifluoromethyl)-1-benzofuran-2-one |
AKOS001738667 |
5,7-di-tert-butyl-3-hydroxy-3-(trifluoromethyl)-1-benzofuran-2(3h)-one |
STK770129 |
bdbm50427614 |
rac bhff |
123557-91-5 |
bhff |
CHEMBL2322946 , |
CCG-222445 |
AKOS022017970 |
SCHEMBL2371840 |
5,7-bis(1,1-dimethylethyl)-3-hydroxy-3(trifluoromethyl)-2(3h)-benzofuranone |
3h-benzofuran-2-one, 5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl- |
DTXSID50402030 |
3-hydroxy-5,7-bis(2-methyl-2-propanyl)-3-(trifluoromethyl)-1-benzofuran-2(3h)-one |
J-004955 |
5,7-bis(1,1-dimethylethyl)-3-hydroxy-3-(trifluoromethyl)-2(3h)-benzofuranone |
rac bhff, >=98% (hplc) |
NCGC00370908-01 |
Q4835587 |
racbhff |
rac-bhff |
(r,s)-bhff |
(r,s)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3h-benzofuran-2-one |
gtpl10267 |
2(3h)-benzofuranone, 5,7-bis(1,1-dimethylethyl)-3-hydroxy-3-(trifluoromethyl)- |
NCGC00370908-10 |
N17055 |
YEA55791 |
HY-103519 |
unii-k3w3822bmv |
k3w3822bmv , |
AS-80062 |
CS-0028020 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 23.9185 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
G | Vesicular stomatitis virus | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Interferon beta | Homo sapiens (human) | Potency | 21.3174 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Gamma-aminobutyric acid type B receptor subunit 2 | Homo sapiens (human) | EC50 (µMol) | 1.9000 | 0.5300 | 1.8736 | 5.3700 | AID729173 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 100.0000 | 0.0190 | 1.7367 | 7.0000 | AID729172 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 100.0000 | 0.0190 | 2.1499 | 10.0000 | AID729172 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 100.0000 | 0.0190 | 1.7367 | 7.0000 | AID729172 |
Gamma-aminobutyric acid type B receptor subunit 1 | Homo sapiens (human) | EC50 (µMol) | 1.9000 | 0.0794 | 1.6276 | 5.3700 | AID729173 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID729166 | Anxiolytic activity in high alcohol preferring-2 mouse assessed as reduction of startle response under noise alone condition at 12.5 mg/kg, ip treated 25 mins prior to test | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor. |
AID1237987 | Positive allosteric modulator activity at GABA-B receptor (unknown origin) assessed as potentiation of GABA-induced [35S]GTPgammaS binding | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | Activation of the γ-Aminobutyric Acid Type B (GABA(B)) Receptor by Agonists and Positive Allosteric Modulators. |
AID729173 | Agonist activity at human GABA-B B1/B2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 3 hrs by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor. |
AID729160 | Anxiolytic activity in high alcohol preferring-2 mouse assessed as reduction of startle response under light and noise condition at 12.5 mg/kg, ip treated 25 mins prior to test | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor. |
AID729172 | Agonist activity at rat GABA-A alpha1beta2gamma2 receptor expressed in human TSA201 cells by whole cell voltage-clamp method | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (4.76) | 29.6817 |
2010's | 16 (76.19) | 24.3611 |
2020's | 4 (19.05) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.76%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (95.24%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |